BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Yin YH, Sang LX, Chang B. Potential therapeutic targets for nonalcoholic fatty liver disease: Glucagon-like peptide 1. World J Gastroenterol 2023; 29(48): 6235-6238 [PMID: 38186863 DOI: 10.3748/wjg.v29.i48.6235]
URL: https://www.wjgnet.com/1007-9327/full/v29/i48/6235.htm
Number Citing Articles
1
Maurizio Soresi, Lydia Giannitrapani. Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver diseaseWorld Journal of Gastroenterology 2024; 30(30): 3541-3547 doi: 10.3748/wjg.v30.i30.3541
2
Pedro Robson Costa Passos, Valbert Oliveira Costa Filho, Mariana Macambira Noronha, Elodie Bomfim Hyppolito, Erick Figueiredo Saldanha, Rodrigo Vieira Motta. Influence of glucagon‐like peptide‐1 receptor agonists on hepatic events in type 2 diabetes: a systematic review and meta‐analysisJournal of Gastroenterology and Hepatology 2024;  doi: 10.1111/jgh.16752